Trial of routine gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma.
OBJECTIVE
To investigate the usefulness of a routine short term treatment with gonadotropin releasing hormone agonist (D-Trp-6-LHRH depot) before abdominal hysterectomy for leiomyoma.


METHODS
Prospective, comparative, randomized study.


METHODS
A teaching hospital of Barcelona University.


METHODS
Fifty premenopausal women requiring hysterectomy as treatment for symptomatic leiomyomas. Twenty-three patients were randomized to receive gonadotropin releasing hormone agonist treatment before hysterectomy (cases), and 27 patients were randomized to immediate hysterectomy (controls).


METHODS
Type of abdominal incision, operating time, operative hemoglobin and hematocrit decrease, postoperative morbidity, and days in hospital.


RESULTS
In the agonist treated group mean uterine volume decreased and mean hemoglobin and hematocrit significantly rose after 8 weeks of treatment. Operative time was similar in both groups of patients but the number of women having Pfannenstiel incision was significantly higher in the cases. Mean operative hemoglobin and hematocrit decrease and postoperative morbidity were lower in the cases. There was a trend for shorter postoperative hospital stays in the agonist treated group.


CONCLUSIONS
Our results favor the routine use of a short term gonadotropin releasing hormone agonist treatment before abdominal hysterectomy for leiomyoma in order to decrease operative blood loss and postoperative morbidity.
Balasch
J
J
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Barcelona, Hospital Clinic i Provincial, Spain.
Manau
D
D
Mimó
J
J
Duran
M
M
Puerto
B
B
Vanrell
J A
JA
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D007902:Length of Stay; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011446:Prospective Studies; D016037:Single-Blind Method; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D017329:Triptorelin Pamoate